Genitourinary Cancers

Charles Ryan, MD, discusses community oncologist prescribing preferences for patients with prostate cancer or renal cell carcinoma.

An exceptional responder with advanced urothelial carcinoma experienced a complete radiologic response lasting 13.8 months following treatment with the combination of everolimus (Afinitor) and pazopanib.

Elizabeth Plimack, MD, MS, attending physician, medical oncology, Fox Chase Cancer Center, discusses a phase I trial that looked at overcoming mTOR resistance with an HDAC inhibitor in renal cell carcinoma (RCC).

Robert Figlin, MD, FACP, discusses an analysis of the heterogeneity of intermediate prognosis patients with metastatic renal cell carcinoma (mRCC) treated with sunitinib.

A review by André P. Fay, MD, on the data supporting the standard use of neoadjuvant and adjuvant chemotherapy for patients with muscle invasive bladder cancers.

David F. McDermott, MD, associate professor, Department of Medicine, Harvard Medical School/Dana-Farber Cancer Institute, discusses the potential of targeting PD-1 or PD-L1 in patients with kidney cancer

Some patients with micropapillary urothelial carcinoma face a three-fold risk of cancer death because their disease amplifies HER2 and overexpresses its protein product, and there may be a role for treatment of the condition with HER2- targeted agent trastuzumab, which has vastly increased the odds of survival for eligible patients with breast cancer.

A study published in the New England Journal of Medicine sparked controversy and criticism when it claimed that many men received unnecessary radiation therapy for their prostate cancer due to self-referral.

Brian Rini, MD, associate professor, Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, discusses professional practice gaps and barriers to optimal care of renal cell carcinoma (RCC).

An inside look at how the Michigan Institute of Urology is navigating the shifting healthcare and civic landscape.

Nizar M. Tannir, MD, FACP, from The University of Texas MD Anderson Cancer Center, discusses a phase I trial of sunitinib and temsirolimus in patients with metastatic renal cell carcinoma.

Arjun Balar, MD, assistant professor of medicine, Division of Hematology & Oncology, New York University Cancer Institute, NYU Langone Medical Center, discusses two trials that evaluate the efficacy of bevacizumab in bladder cancer.

High tumor expression of the protein PD-L1 is independently associated with shorter OS in patients with mRCC receiving treatment with VEGF-targeted therapy.

Two new combinations demonstrated activity in refractory or advanced, previously untreated urothelial carcinoma in phase II evaluations.